Peptides as NS3-serine protease inhibitors of hepatitis C virus

Details for Australian Patent Application No. 2001276988 (hide)

Owner Schering Corporation Dendreon Corporation

Inventors Pike, Russell E; Girijavallabhan, Viyyoor Moopil; Pinto, Patrick A.; Liu, Yi-Tsung; Tamura, Susan Y; Lovey, Raymond G.; Santhanam, Bama; Chan, Tin-Yau; Saksena, Anil K.; Chen, Kevin X.; Levy, Odile Esther; Hendrata, Siska; Venkatraman, Srikanth; Bogen, Stephane L.; Zhu, Zhaoning; Wang, Haiyan; Kemp, Scott Jeffrey; Vaccaro, Henry, A.; Parekh, Tejal N.; Huang, Yuhua; Ganguly, Ashit K.; Jao, Edwin E.; Arasappan, Ashok; Lim-Wilby, Marguerita; Wu, Wanli; Bennett, Frank; Njoroge, F. George; Mc Cormick, Jinping L

Agent Griffith Hack

Pub. Number AU-B-2001276988

PCT Pub. Number WO02/08244

Priority 60/220,108 21.07.00 US

Filing date 19 July 2001

Wipo publication date 5 February 2002

Acceptance publication date 25 January 2007

International Classifications

A61K 45/00 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

A61K 31/7056 (2006.01)

A61K 38/00 (2006.01) Medicinal preparations containing peptides

A61K 38/21 (2006.01) Medicinal preparations containing peptides - Interferons

A61P 31/14 (2006.01) Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

A61P 43/00 (2006.01) Drugs for specific purposes, not provided for in groups

C07K 5/02 (2006.01) Peptides having up to four amino acids in a fully defined sequence

C07K 5/08 (2006.01) Peptides having up to four amino acids in a fully defined sequence

C07K 7/02 (2006.01) Peptides having 5 to 20 amino acids in a fully defined sequence

Event Publications

6 May 2004 Assignment before Grant

  Schering Corporation; Corvas International, Inc. The application has been assigned to Schering Corporation; Dendreon Corporation

25 January 2007 Application Accepted

  Published as AU-B-2001276988

24 May 2007 Standard Patent Sealed

12 July 2012 Extension of Term of Standard Patents

  Schering Corporation ; Dendreon Corporation The earliest first regulatory approval date provided by the patentee 09 Jan 2012 For the goods VICTRELIS boceprevir

2 August 2012 Extension of Term of Standard Patents

  Schering Corporation; Dendreon Corporation The earliest first regulatory approval date provided by the patentee 09 Jan 2012 For the goods VICTRELIS boceprevir Address for service in Australia: Griffith Hack Level 29, Northpoint 100 Miller Street North Sydney NSW 2060

4 October 2012 Alteration of Name

  The name of the patentee has been altered to Dendreon Corporation; Merck Sharp & Dohme Corp. 2002

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2001276989

2001276987